Active, not recruitingPhase 2NCT05725902

Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease

Studying Sickle cell disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Novo Nordisk A/S
Principal Investigator
Clinical Transparency dept. 2834
Novo Nordisk A/S
Intervention
Etavopivat(drug)
Enrollment
12 enrolled
Eligibility
12-21 years · All sexes
Timeline
20242026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05725902 on ClinicalTrials.gov

Other trials for Sickle cell disease

Additional recruiting or active studies for the same condition.

See all trials for Sickle cell disease

← Back to all trials